Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00513266
First received: August 6, 2007
Last updated: August 6, 2009
Last verified: June 2009
  Purpose

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with monoclonal antibody therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with monoclonal antibody therapy works in treating patients with advanced colorectal cancer with liver metastases or lung metastases that are potentially removable by surgery.


Condition Intervention Phase
Colorectal Cancer
Metastatic Cancer
Biological: bevacizumab
Biological: cetuximab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Other: laboratory biomarker analysis
Procedure: adjuvant therapy
Procedure: biopsy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response as assessed by NCIC criteria [ Designated as safety issue: No ]
  • Toxicity as assessed by NCIC criteria [ Designated as safety issue: Yes ]

Estimated Enrollment: 35
Study Start Date: June 2007
Detailed Description:

OBJECTIVES:

Primary

  • To determine the pathological complete response (CR) rate in resected patients assessed on lesions of less than or equal to 30 mm in size.

Secondary

  • To determine the clinical CR rate in all patients.
  • To determine toxicity and tolerability of this regimen (pre- and postoperative toxicity).
  • To evaluate perioperative safety in these patients.
  • To determine disease-free survival (time to progression in unresected patients) and overall survival of the whole study population.
  • To determine resectability in these patients.
  • To evaluate markers that predict the occurrence of a pathological CR or a non-response in pathological material (resected liver metastasis) and biological material collected from these patients.

OUTLINE: This is a multicenter study.

Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, oxaliplatin IV over 2 hours on days 1 and 15, irinotecan hydrochloride IV over 30 minutes on days 8 and 22, fluorouracil IV over 24 hours on days 1, 8, 15, and 22, leucovorin calcium IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 5 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Patients who are able to undergo liver resection receive bevacizumab on day 1 only of course 3 and undergo liver resection 3 weeks after chemotherapy. Beginning 4 weeks after liver resection, patients receive 2 additional courses of chemotherapy as adjuvant therapy.

Patients undergo tumor tissue and blood sample collection periodically for biological studies. Samples are analyzed for markers that predict the occurrence of a complete pathological response (pCR) or a non-response.

After completion of study treatment, patients are followed every 3 months for the first 2 years and then every 6 months thereafter.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Histologically confirmed metastatic colorectal adenocarcinoma
  • Bidimensionally measurable metastatic disease limited to the liver and considered curatively resectable after response to systemic therapy as assessed by a surgical board

    • Additional metastatic disease to the lungs consisting of no more than 3 potentially resectable lesions allowed
    • Must have at least one lesion of 30 mm or less

Exclusion criteria:

  • History or evidence upon physical examination of CNS disease unless adequately treated (e.g., uncontrolled seizure with standard medical therapy or history of stroke)

PATIENT CHARACTERISTICS:

Inclusion criteria:

  • Performance status ≤ 1
  • Life expectancy > 12 weeks
  • WBC ≥ 3,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine 1.25 x upper limit of normal (ULN)
  • Bilirubin 1.25 x ULN (1.5 x ULN if liver metastasis)
  • AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastasis)
  • Woman and men of childbearing age must use adequate contraception

Exclusion criteria:

  • Pregnancy (positive serum pregnancy test) or lactation
  • Chronic diarrhea ≥ grade 2
  • Other serious illness or medical condition including any of the following:

    • Unstable cardiac disease requiring treatment
    • Congestive heart failure or angina pectoris even if medically controlled
    • Significant arrhythmias
    • History of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent
    • Active uncontrolled infection
    • Severe hypercalcemia
    • Other serious underlying medical condition that could impair the ability of the patient to participate in the study
    • Neuropathy > grade 1 of any etiology
  • Known DPD deficiency
  • Known severe polyneuropathy
  • Known allergy to Chinese hamster ovary cell proteins, other recombinant human or humanized antibodies, any excipients of bevacizumab formulation, or any other study drugs
  • Chronic inflammatory bowel disease
  • Acute or subacute intestinal occlusion
  • History of previous arterial thromboembolism
  • Uncontrolled hypertension
  • Evidence of bleeding diathesis or coagulopathy
  • Serious nonhealing wound, ulcer, or bone fracture
  • History of tumor other than basocellular carcinoma of the skin
  • Peripheral neuropathy > grade 1 of any origin (e.g., alcohol)
  • Significant traumatic injury within 28 days prior to study treatment

PRIOR CONCURRENT THERAPY:

Exclusion criteria:

  • No prior chemotherapy for metastatic disease

    • Prior adjuvant chemotherapy permitted if interval since last treatment administration and recurrence is > 6 months
  • Major surgical procedure or open biopsy within 28 days prior to study treatment or anticipation of the need for major surgical procedure during the course of the study
  • Treatment in a clinical trial within 30 days prior to study entry
  • Concurrent treatment with other experimental drugs or other anticancer therapy
  • Current or recent use (within 10 days prior to study treatment) of full-dose oral or parenteral anticoagulants for therapeutic purposes
  • Chronic daily treatment with aspirin (> 325 mg/day)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00513266

Locations
Switzerland
Kantonspital Aarau
Chur, Switzerland, CH-7000
Hopital Cantonal Universitaire de Geneve
Geneva, Switzerland, CH-1211
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Hopital Regional de Sion-Herens-Conthey
Sion, Switzerland, CH -1951
Sponsors and Collaborators
Centre Hospitalier Universitaire Vaudois
Investigators
Study Chair: Arnaud Roth, MD Hopital Cantonal Universitaire de Geneve
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00513266     History of Changes
Other Study ID Numbers: CDR0000559146, CHUV-CH-OCFL-BC, EU-20741
Study First Received: August 6, 2007
Last Updated: August 6, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent rectal cancer
stage IV rectal cancer
recurrent colon cancer
stage IV colon cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum
liver metastases
lung metastases

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Bevacizumab
Oxaliplatin
Cetuximab
Irinotecan
Fluorouracil
Levoleucovorin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses
Antineoplastic Agents, Phytogenic
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on September 18, 2014